A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CFT 8634 (Primary)
Indications Solid tumours; Synovial sarcoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors C4 Therapeutics

Most Recent Events

18 Jan 2024 Status changed from active, no longer recruiting to discontinued.
10 Nov 2023 Planned End Date changed from 1 May 2025 to 1 Jan 2024.
10 Nov 2023 Planned primary completion date changed from 1 Oct 2024 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight